TORONTO, ONTARIO--(Marketwire - August 08, 2008) - Lorus Therapeutics Inc. (TSX: LOR)(AMEX: LRP) ("Lorus"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced that it has successfully completed its rights offering to eligible shareholders raising total gross proceeds of $3.71 million.
